Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug–Drug Interactions

Clinical Pharmacokinetics

Volumn 54, Issue 12, 2015, Pages 1205-1222

  Eley, Timothy ^a   Garimella, Tushar ^a   Li, Wenying ^a   Bertz, Richard J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; BECLABUVIR; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; DACLATASVIR; MULTIDRUG RESISTANCE PROTEIN; ANTIVIRUS AGENT; CYTOCHROME P450 3A; ISOQUINOLINE DERIVATIVE; NS3 PROTEIN, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; SULFONAMIDE; VIRAL PROTEIN;

AEROBIC METABOLISM; DRUG ABSORPTION; DRUG FORMULATION; DRUG INTERACTION; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; ELIMINATION HALF-LIFE; FECES; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPANESE (PEOPLE); MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORAL CLEARANCE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STEADY STATE; URINARY EXCRETION; ANIMAL; ANTAGONISTS AND INHIBITORS; HEPATITIS C, CHRONIC; METABOLISM;

ANIMALS; ANTIVIRAL AGENTS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; ISOQUINOLINES; PROTEASE INHIBITORS; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84948586560     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0299-6     Document Type: Review

References (50)

1. Gower E, Estes CC, Hindman S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(S1):S45–57.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–21 (521.e1-6).
4. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.
5. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.
6. Vertex Pharmaceuticals Incorporated. Incivek™ (telaprevir) film coated tablets: prescribing information. US Food and Drug Administration. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf. Accessed 22 Jun 2015.
7. Schering Corporation. Victrelis™ (boceprevir) capsules: prescribing information. US Food and Drug Administration. May 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf. Accessed 22 Jun 2015.
8. Gogela NA, Lin MV, Wisocky JL, Chung RT. Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep. 2015;12:68–78.
9. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;60:392–420.
10. McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012;56:5387–96.
11. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:414–29.
12. Bronowicki JP, Ratziu V, Gadano A, Thuluvath PJ, Bessone F, Martorell CT, et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. J Hepatol. 2014;61:1220–7.
13. Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146:420–9.
14. Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, et al. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014;57:1730–52.
15. Mosure KW, Knipe JO, Browning M, Arora V, Shu Y-Z, Thomas P, et al. Preclinical pharmacokinetics and in vitro metabolism of asunaprevir: a potent HCV NS3 protease inhibitor. J Pharm Sci. 2015;. doi:10.1002/jps.24356.
16. Eley T, Han YH, Huang S, He B, Li W, Bedford W, et al. Organic anion–transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease. Clin Pharm Ther. 2015;97:159–66.
17. Eley T, He B, Huang S, Li W, Pasquinelli C, Rodrigues AD, et al. Pharmacokinetics of the NS3 protease inhibitor, asunaprevir (ASV, BMS-650032), in phase I studies in subjects with or without chronic hepatitis C. Clin Pharmacol Drug Dev. 2013;2(4):316–27.
18. Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Wendelburg P, et al. Single and multiple ascending dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012;56:1838–44.
19. Shiozaki T, Ueno T, Nagashima H, Yamahira N, Hiraoka M, Eley T, et al. Single and multiple-ascending dose studies to evaluate the safety, tolerability and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects. Int J Clin Pharmacol Ther. 2015;53(4):292–302.
20. Eley T, Sevinsky H, Huang SP, He B, Zhu K, Kandoussi H, et al. The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus. Clin Drug Investig. 2014;34:661–71.
21. Eley T, Colston E, Li J, Garimella T, He B, Dutta A, et al. Asunaprevir does not have an effect on QTcF interval in healthy subjects [poster no. P_53]. In: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington, DC; 19–21 May 2014.
22. Eley T, Chan P, Sverdlov O, He B, Bedford B, Kandoussi H, et al. Improved bioavailability and mitigated food effect for asunaprevir utilizing a lipid-based formulation: similar exposure with 100 mg twice-daily soft-gel capsule relative to 200 mg twice daily of phase 2 tablet [abstract/poster no. A-1247]. In: 52nd Interscience Conference Antimicrobial Agents Chemotherapy. San Francisco; 9–12 Sep 2012.
23. Eley T, Gardiner D, Persson A, He B, You X, Shah V, et al. Evaluation of drug interaction potential of the HCV protease inhibitor asunaprevir (ASV; BMS-650032) at 200 mg twice daily in metabolic cocktail and P-glycoprotein (P-gp) probe studies in healthy volunteers [abstract]. Hepatology. 2011;54:abstract no. 381.
24. Morcos PN, Moreira SA, Brennan BJ, Blotner S, Shulman NS, Smith PF. Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. Eur J Clin Pharmacol. 2013;69:1777–84.
25. Eley T, Chan P, Huang S, Wind-Rotolo M, Delmonte T, He B, et al. Asunaprevir in Japanese subjects in phase 2: exposure-safety versus US/EU-based subjects and preliminary assessment of correlation with single nucleotide polymorphisms (SNPs) in liver uptake transporters. Hepatology. 2012;56(Suppl 1):1070A–1A.
26. Garimella T, Li W, Wind-Rotolo M, He B, Zhu L, Chan P, et al. Assessment of correlation of asunaprevir with polymorphisms in liver uptake transporters (OATP1B1 and 2B1): results of an integrated population PK analyses [poster no. pp-32]. In: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington, DC; 19–21 May 2014.
27. Zhu L, Li H, Chan P, Eley T, Bifano M, Osawa M, et al. Population pharmacokinetic analysis of asunaprevir in subjects with hepatitis C virus (HCV) infection [poster no. T-001]. American Conference on Pharmacometrics (ACoP) Meeting. Las Vegas; 12–15 Oct 2014.
28. Kikuchi R, McCown M, Olson P, Tateno C, Morikawa Y, Katoh Y, et al. Effect of hepatitis C virus infection on the mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric mice with humanized liver. Drug Metab Dispos. 2010;38:1954–61.
29. +-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion–transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab Dispos. 2008;36:1786–93.
30. Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet. 2008;47:743–52.
31. Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49:189–206.
32. Eley T, He B, Chang I, Colston E, Child M, Bedford W, et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther. 2015;20(1):29–37.
33. Garimella T, He B, Luo W, Colston E, Zhu K, Kandoussi H, et al. Asunaprevir pharmacokinetics and safety in subjects with impaired renal function. Hepatology. 2013;58:430A.
34. Bronowicki JP, Pol S, Thuluvath PJ, Larrey D, Martorell CT, Rustgi VK, et al. Randomized study of asunaprevir plus pegylated interferon-alpha and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther. 2013;18:885–93.
35. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216–24.
36. Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, et al. Randomized trial of daclatasvir and asunaprevir with or without pegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014;60:490–9.
37. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91.
38. Chan P, Zhu L, Eley T, Bifano M, Hughes E, Bertz R. Exposure-safety analysis for asunaprevir and daclatasvir in dual combination in subjects with hepatitis C virus infection. J Pharmacokinet Pharmacodyn. 2014;41:S7.
39. Wang X, Li W, Huang S, He B, Chung E, Griffies A, et al. Evaluation of pharmacokinetic drug–drug interaction (DDI) between BMS-791325, an NS5B non-nucleoside polymerase inhibitor, daclatasvir and asunaprevir in triple combination in HCV genotype 1-infected patients [abstract]. J Hepatol. 2013;58(Suppl 1):S184.
40. Poordad F, Sievert W, Mollison L, Brau N, Levin J, Sepe T, et al. All-oral fixed-dose combination therapy with daclatasvir/asunaprevir/BMS-791325 for non-cirrhotic patients with HCV genotype 1 infection: UNITY-1 phase 3 SVR12 results. Hepatology. 2014;60:1271A–2A.
41. Muir A, Poordad F, Lalezari JP, Everson GT, Dore GJ, Kwo P, et al. All-oral fixed-dose combination therapy with daclatasvir/asunaprevir/BMS-791325, ±ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY-2 phase 3 SVR12. Hepatology. 2014;60:1267A–8A.
42. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet. 2012;27:55–67.
43. Garimella T, Adamczyk R, Hu P, Stonier M, Kandoussi H, Colston E, et al. No clinically-relevant interactions between asunaprevir and selective serotonin reuptake inhibitors (escitalopram and sertraline) in healthy subjects. Hepatology. 2013;58(4 Suppl):445A.
44. Garimella T, Eley T, He B, Luo W, Crowell J, Kandoussi H, et al. Evaluation of drug–drug interactions between asunaprevir and methadone or buprenorphine/naloxone [poster no. 823]. IDWeek 2014. Philadelphia; 8–12 Oct 2014.
45. Eley T, He B, Huang S, Stonier M, Bedford W, Kandoussi H, et al. Effect of multiple-dose ketoconazole and the effect of multiple-dose rifampin on the pharmacokinetics (PK) of the NS3 protease inhibitor asunaprevir. Reviews in Antiviral Therapy and Infectious Diseases. 2013;6:15.
46. Shitara Y, Takeuchi K, Nagamatsu Y, Wada S, Sugiyama Y, Horie T. Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake. Drug Metab Pharmacokinet. 2012;27:368–78.
47. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565–81.
48. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655–62.
49. Hassanein T, Sims K, Bennett M, Gitlin N, Lawitz E, Nguyen T, et al. All-oral therapy with daclatasvir in combination with asunaprevir and BMS-791325 in treatment-naive patients with chronic HCV genotype 4 infection [abstract no. 1163]. J Hepatol. 2014;60(Suppl 1):S472.
50. Jensen D, Sherman K, Hézode C, Pol S, Zeuzem S, De Ledinghen V, et al. Daclatasvir and asunaprevir plus peginterferon alfa-2a and ribavirin in patients with HCV genotype 1 or 4 infection: phase 3 HALLMARK-QUAD results [poster no. 821]. ID Week 2014. Philadelphia; 8–12 Oct 2014.